Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis. Read more on CMPS stock here.

The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.

Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...

Compass announced in January that the FDA had accepted its Investigational New Drug application for COMP360 for the treatment ...

COMPASS Pathways CMPS shares are up during Tuesday’s premarket session following the company’s announcement of achieving the ...

The latest readout, from the COMP006 study, showed that two doses of the highest, 25 mg dose of COMP360, given in a controlled environment with psychological support from a trained therapist, were ...

Compass shares are trading at $5.89, near their 52-week high of $6.88 and well above the $1.33 low touched last year. Recent analyst activity underscores the bullish sentiment. Craig-Hallum initiated ...

CTX-009 demonstrated a 42% overall response rate (ORR) based on 10 patients with Partial Responses (PRs), including 9 PRs confirmed by RECIST 1.1 and 1 PR pending confirmation CTX-009 demonstrated ...

CHICAGO--(BUSINESS WIRE)-- ComEd today joined Compass Datacenters, the Village of Hoffman Estates and area leaders to formally launch one of the largest-ever Illinois data center projects. The new ...